CAR-T cell manufacturing: Major process parameters and next-generation strategies.
J Exp Med
; 221(2)2024 Feb 05.
Article
in En
| MEDLINE
| ID: mdl-38226974
ABSTRACT
Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy treatments. Successful deployment of CAR-T cell therapies to treat hematologic and solid cancers, as well as other indications such as autoimmune diseases, is dependent on effective CAR-T cell manufacturing that impacts not only product safety and efficacy but also overall accessibility to patients in need. In this review, we discuss the major process parameters of autologous CAR-T cell manufacturing, as well as regulatory considerations and ongoing developments that will enable the next generation of CAR-T cell therapies.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Autoimmune Diseases
Limits:
Humans
Language:
En
Journal:
J Exp Med
/
J. exp. med
/
Journal of experimental medicine
Year:
2024
Type:
Article
Affiliation country:
United States